

RECEIVED
AUG 03 2004
OFFICIALBOX: PATENT APPLICATION
Atty. Docket No.: 82,197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: Callahan et al

Serial No.: 09/726,345

Filing Date: December 1, 2000

Title: SEROTYPE AND DENGUE GROUP SPECIFIC FLUROGENIC PROBE-BASED
PCR (TAQMAN) ASSAYS AGAINST THE RESPECTIVE C AND NS5 GENOMIC AND 3'
NON-CODING REGIONS OF DENGUE VIRUSTRANSMITTAL LETTERCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Submitted herewith for filing in the U. S. Patent and Trademark Office is the following:


- (1) Amendment - 3 pages
- (2) Copy of Record and Disclosure of Invention (Appendix A) - 4 pages
- (3) Affidavit Under 37 CFR 1.131 (Appendix B) - ~~4~~ 4 pages

Please credit any overpayments or debit any additional fees to Deposit Account No. 14-0595.

Respectfully,


Philip E. Ketner
Reg. No. 46,272

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile reproduction to the Patent and
Trademark Office, (703) 872-9306 on the date shown below.

Date 8/3/2004

AUG 03 2004

OFFICIAL

Docket No. 82,197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callahan, et al.

Application No. 09/726,345

Filed: 12/01/2000

For: SEROTYPE AND DENGUE GROUP SPECIFIC
FLUROGENIC PROBE-BASED PCR (TAQMAN)
ASSAYS AGAINST THE RESPECTIVE C AND NS5
GENOMIC AND 3' NON-CODING REGIONS OF
DENGUE VIRUS

Examiner: T. Garvey

Group Art Unit: 1636

July 29, 2004

AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This communication is responsive to your Office Action mailed on July 14, 2004.

Claims 18 is pending in this application. Claim 18 is subject to a non-final rejection by the Examiner.

Please amend the above-identified application as follows:

Amendments to the Specification begins on page 2 of this paper.

Remarks begin on page 3 of this paper.

Appendix A, an invention disclosure showing the dates of conception of the instant invention as
discussed in the accompanying affidavit, is attached following page 3 of this paper.

Appendix B, the 37 CFR 1.131 Affidavit, is attached following Appendix A.